60 related articles for article (PubMed ID: 16857827)
1. Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
Johnson DH
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4451s-4457s. PubMed ID: 16857827
[TBL] [Abstract][Full Text] [Related]
2. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
[TBL] [Abstract][Full Text] [Related]
4. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
5. Optimizing therapy in previously treated non-small cell lung cancer.
Miller VA
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S25-31. PubMed ID: 16472706
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
7. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Patel JD
Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
[TBL] [Abstract][Full Text] [Related]
9. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
10. EGFR FISH versus mutation: different tests, different end-points.
Cappuzzo F
Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutations in lung cancer.
Sharma SV; Bell DW; Settleman J; Haber DA
Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
[TBL] [Abstract][Full Text] [Related]
12. EGF receptor in lung cancer: a successful story of targeted therapy.
Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
[TBL] [Abstract][Full Text] [Related]
13. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):976-83. PubMed ID: 14967459
[TBL] [Abstract][Full Text] [Related]
14. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma.
Belani CP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):25-33. PubMed ID: 15726531
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results.
Lara PN; Ramalingam SS
Clin Lung Cancer; 2008 May; 9(3):141-3. PubMed ID: 18621622
[No Abstract] [Full Text] [Related]
16. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.
Krause M; Gurtner K; Deuse Y; Baumann M
Int J Radiat Biol; 2009 Nov; 85(11):943-54. PubMed ID: 19895271
[TBL] [Abstract][Full Text] [Related]
17. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
de Jonge MJ; Verweij J
Eur J Cancer; 2006 Jul; 42(10):1351-6. PubMed ID: 16740386
[TBL] [Abstract][Full Text] [Related]
18. [Methodology for the assessment of new targeted treatments in clinical trials. Future perspectives].
Quoix E
Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S72-8. PubMed ID: 15536358
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?
Xu JM; Paradiso A; McLeod HL
Eur J Cancer; 2004 Aug; 40(12):1807-9. PubMed ID: 15288280
[No Abstract] [Full Text] [Related]
20. Trial offers new model for drug development.
Cancer Discov; 2014 Mar; 4(3):266-7. PubMed ID: 24596189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
